Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
The patient received the first dose on 30-Dec-2025 and has not resumed the remainder of the series.; Case reference number US-BN-2026-000101 is a spontaneous case initially received from pharmacist via Bavarian Nordic (reference number: CASE-001656) on 19-Jan-2026 and concerns a 25-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 30-Dec-2025, the patient received the first dose of RabAvert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration for indication reported as dog bite requiring the RabAvert series. As reported, the patient received only one dose of RabAvert and he was planning to receive the second dose; however, the interval since the first dose was longer than recommended (explicitly coded as 'incomplete course of vaccination') At the time of initial report, it was unknown if the patient experienced any adverse event due to RabAvert. No further information was provided.; Reporter's Comments: A 25-year-old male patient received only one dose of RabAvert for indication reported as dog bite requiring the RabAvert series, and he was planning to receive the second dose; however, the interval since the first dose was longer than recommended, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to RabAvert. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 25-year-old male patient received only one dose of RabAvert for indication reported as dog bite requiring the RabAvert series, and he was planning to receive the second dose; however, the interval since the first dose was longer than recommended, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to RabAvert. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.